IDH2 and acute myeloid leukemia: Acute myeloid leukemia with mutations in TET2 or IDH2 is sensitive to epigenetic therapy involving the inhibition of DNA methyltransferase activity using 5-azacytidine or the inhibition of mutant IDH2.